Document Detail


Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
MedLine Citation:
PMID:  15182131     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Castleman's is an uncommon lymphoproliferative disorder secondary to lymphoid follicle hyperplasia and marked capillary proliferation with endothelial hyperplasia. This illness can be associated with glomerulonephritis (GN). Here, we report a case with steroid-dependent nephrotic syndrome secondary to proliferative mesangial glomerulonephritis in a patient with Castleman's disease, that was diagnosed several years before. Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome. Our experience suggests a possible role of thalidomide in the treatment of glomerular pathology when a role of IL-6 is hypothesized.
Authors:
M Adorati Menegato; M Fanni Canelles; E Tonutti; S Pizzolitto
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  61     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-06-08     Completed Date:  2005-03-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  352-6     Citation Subset:  IM    
Affiliation:
Nephrology and Dialysis Unit, Ospedale Sant Antonio, ASS 4 Medio Friuli, Italy. ndsd@ass4.sanita.fvg.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biopsy
Female
Giant Lymph Node Hyperplasia / complications*
Glomerulonephritis, Membranoproliferative / complications*,  drug therapy,  pathology
Humans
Immunosuppressive Agents / therapeutic use*
Kidney Glomerulus / pathology
Nephrotic Syndrome / drug therapy*,  etiology
Thalidomide / therapeutic use*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C...
Next Document:  Renal transplantation in a C-ANCA(+) patient with Behcet disease and rapidly progressive glomerulone...